A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer

Trial Profile

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Selumetinib (Primary) ; Iodine radioactive
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Planned End Date changed from 1 May 2019 to 5 Jul 2019.
    • 01 Mar 2017 Planned primary completion date changed from 1 Nov 2017 to 8 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top